Latest News from Origin
Origin Capital co-leads £2.1m investment in platform biotech Somaserve
Origin Capital was the largest investor in a £2.1m funding round recently completed by Somaserve, a developer of specialised nanoparticle technologies for delivery of pharmaceutical and other therapeutic agents to targeted cell types. Read more here.
